Stockreport

Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent a- and ß-Thalassemia at the European Hematology Association Virtual Congress

Agios Pharmaceuticals, Inc.  (AGIO) 
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.agios.com/investor-overview
PDF – Study Met Primary Endpoint; Treatment with Mitapivat Induced Hemoglobin Increase of =1.0 g/dL in 16 of 20 (80%) Patients During Weeks 4-12 – – Mitapivat Safety Prof [Read more]